ATE244220T1 - Neue heterocyclische verbindungen, verfahren zu deren herstellung sowie medizinische verwendung - Google Patents
Neue heterocyclische verbindungen, verfahren zu deren herstellung sowie medizinische verwendungInfo
- Publication number
- ATE244220T1 ATE244220T1 AT95932172T AT95932172T ATE244220T1 AT E244220 T1 ATE244220 T1 AT E244220T1 AT 95932172 T AT95932172 T AT 95932172T AT 95932172 T AT95932172 T AT 95932172T AT E244220 T1 ATE244220 T1 AT E244220T1
- Authority
- AT
- Austria
- Prior art keywords
- inhibitors
- pharmaceutically acceptable
- production
- acat
- heterocyclic compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
- C07D215/06—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms having only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/24—Oxygen atoms attached in position 8
- C07D215/26—Alcohols; Ethers thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP22516694A JP3720395B2 (ja) | 1994-09-20 | 1994-09-20 | 新規ヘテロ環誘導体、その製造方法およびその医薬用途 |
PCT/JP1995/001873 WO1996009287A1 (fr) | 1994-09-20 | 1995-09-20 | Nouveaux derives heterocycliques, leur procede de production et leur utilisation medicinale |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE244220T1 true ATE244220T1 (de) | 2003-07-15 |
Family
ID=16824983
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT01114083T ATE255091T1 (de) | 1994-09-20 | 1995-09-20 | 1-acetyl-5-bromo-4,6-dimethylindolin |
AT95932172T ATE244220T1 (de) | 1994-09-20 | 1995-09-20 | Neue heterocyclische verbindungen, verfahren zu deren herstellung sowie medizinische verwendung |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT01114083T ATE255091T1 (de) | 1994-09-20 | 1995-09-20 | 1-acetyl-5-bromo-4,6-dimethylindolin |
Country Status (13)
Country | Link |
---|---|
US (4) | US5990150A (de) |
EP (2) | EP1136474B1 (de) |
JP (1) | JP3720395B2 (de) |
KR (1) | KR100365503B1 (de) |
AT (2) | ATE255091T1 (de) |
AU (1) | AU693261B2 (de) |
CA (1) | CA2200472A1 (de) |
DE (2) | DE69531213T2 (de) |
DK (2) | DK0782986T3 (de) |
ES (2) | ES2206367T3 (de) |
HK (1) | HK1040513B (de) |
PT (2) | PT782986E (de) |
WO (1) | WO1996009287A1 (de) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3720395B2 (ja) | 1994-09-20 | 2005-11-24 | 京都薬品工業株式会社 | 新規ヘテロ環誘導体、その製造方法およびその医薬用途 |
CZ292632B6 (cs) * | 1995-10-05 | 2003-11-12 | Kyoto Pharmaceutical Industries, Ltd. | Indolinový, indolový nebo tetrahydrochinolinový derivát a farmaceutický přípravek s jeho obsahem |
US5861496A (en) * | 1996-11-07 | 1999-01-19 | Incyte Pharmaceuticals, Inc. | Human squalene epoxidase |
US20060046841A1 (en) * | 2004-11-12 | 2006-03-02 | Walker Jay S | Budget-based flat rate play contract parameters |
AR008331A1 (es) * | 1997-01-23 | 1999-12-29 | Smithkline Beecham Corp | Compuestos antagonistas de un receptor de il-8, uso de los mismos para la fabricacion de medicamentos, procedimiento para su obtencion, composicionesfarmaceuticas que los contienen |
US5929250A (en) * | 1997-01-23 | 1999-07-27 | Smithkline Beecham Corporation | IL-8 receptor antagonists |
AR015425A1 (es) * | 1997-09-05 | 2001-05-02 | Smithkline Beecham Corp | Compuestos de benzotiazol, composicion farmaceutica que los contiene, su uso en la manufactura de un medicamento, procedimiento para su preparacion,compuestos intermediarios y procedimiento para su preparacion |
US6673827B1 (en) | 1999-06-29 | 2004-01-06 | The Uab Research Foundation | Methods of treating fungal infections with inhibitors of NAD synthetase enzyme |
US6861448B2 (en) * | 1998-01-14 | 2005-03-01 | Virtual Drug Development, Inc. | NAD synthetase inhibitors and uses thereof |
CA2317439A1 (en) | 1998-01-14 | 1999-07-22 | Wayne J. Brouillette | Methods of synthesizing and screening inhibitors of bacterial nad synthetase enzyme, compounds thereof, and methods of treating bacterial and microbial infections with inhibitors of bacterial nad synthetase enzyme |
PL346178A1 (en) * | 1998-07-23 | 2002-01-28 | Smithkline Beecham Corp | Il-8 receptor antagonists |
FR2783519B1 (fr) | 1998-09-23 | 2003-01-24 | Sod Conseils Rech Applic | Nouveaux derives d'amidines, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant |
SK2552003A3 (en) * | 2000-09-01 | 2003-08-05 | Sankyo Co | Medicinal compositions for the treatment and prevention of xanthoma and atherosclerosis |
TW200600497A (en) * | 2001-02-02 | 2006-01-01 | Sankyo Co | Preparation of indoline derivative |
WO2002072147A1 (fr) * | 2001-03-14 | 2002-09-19 | Sankyo Company, Limited | Compositions medicinales contenant un inhibiteur de transporteur d'acide biliaire |
MXPA04001878A (es) * | 2001-08-28 | 2004-06-15 | Sankyo Co | Composiciones medicinales que comprenden antagonista del receptor de angiotensina ii. |
US20050119314A1 (en) * | 2002-04-05 | 2005-06-02 | Sankyo Company, Limited | Pharmaceutical composition comprising an ACAT inhibitor and an insulin resistance reducing agent |
EP1541553B1 (de) | 2002-07-17 | 2010-06-02 | Kyoto Pharmaceutical Industries, Ltd. | Indolinverbindung und deren medizinische verwendung |
US7205329B2 (en) * | 2003-05-30 | 2007-04-17 | Microbia, Inc. | Modulators of CRTH2 activity |
US20070161698A1 (en) * | 2003-05-30 | 2007-07-12 | Microbia, Inc. | Modulators of CRTH2 Activity |
WO2005002525A2 (en) * | 2003-07-01 | 2005-01-13 | Microbia, Inc. | Cox-2 and faah inhibitors |
US20070293542A1 (en) * | 2003-10-16 | 2007-12-20 | Cali Brian M | Selective Cox-2 Inhibitors |
EP1689383B1 (de) | 2003-11-19 | 2012-10-31 | Metabasis Therapeutics, Inc. | Neue phosphor enthaltende thyromimetika |
US20050234244A1 (en) * | 2004-04-20 | 2005-10-20 | Wilmin Bartolini | Synthesis of COX-2 and FAAH inhibitors |
US20050234030A1 (en) * | 2004-04-20 | 2005-10-20 | Wilmin Bartolini | Modulators of CRTH2, COX-2 and FAAH |
US9164104B2 (en) | 2004-10-06 | 2015-10-20 | The Brigham And Women's Hospital, Inc. | Relevance of achieved levels of markers of systemic inflammation following treatment |
AU2005297984B2 (en) * | 2004-10-27 | 2009-11-12 | Daiichi Sankyo Company, Limited | Benzene compound having 2 or more substituents |
US8022188B2 (en) * | 2006-04-24 | 2011-09-20 | Abbott Laboratories | Immunosuppressant binding antibodies and methods of obtaining and using same |
US7883855B2 (en) | 2006-07-21 | 2011-02-08 | Abbott Laboratories | Immunosuppressant drug extraction reagent for immunoassays |
US7914999B2 (en) * | 2006-12-29 | 2011-03-29 | Abbott Laboratories | Non-denaturing lysis reagent |
ES2393135T3 (es) * | 2006-12-29 | 2012-12-18 | Abbott Laboratories | Ensayo mejorado para fármacos inmunosupresores |
ES2405364T3 (es) | 2006-12-29 | 2013-05-30 | Abbott Laboratories | Ensayo diagnóstico para la detección de una molécula o fármaco en sangre entera |
CA2673314C (en) * | 2006-12-29 | 2014-03-11 | Abbott Laboratories | Non-denaturing lysis reagent for use with capture-in-solution immunoassay |
CN101946179B (zh) * | 2007-12-19 | 2014-08-13 | 雅培制药有限公司 | 用于免疫分析的免疫抑制剂药物提取试剂 |
US20120046364A1 (en) | 2009-02-10 | 2012-02-23 | Metabasis Therapeutics, Inc. | Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1169450B (de) * | 1960-08-19 | 1964-05-06 | Hoechst Ag | Verfahren zur Herstellung von Indolinderivaten und deren Salzen |
US3824230A (en) * | 1969-11-03 | 1974-07-16 | Upjohn Co | 1,2,4,5-tetrahydropyrrolo(3,2,1-jk)(1,4)benzodiazepin-7(6h)-ones and 1,2,4,5-tetrahydropyrrolo(1,2,3-ef)(2,5)benzodiazepin-6(7h)-ones |
JPS5484572A (en) * | 1977-12-14 | 1979-07-05 | Mitsui Petrochem Ind Ltd | Preparation of 1-acyl-5-bromoindoline |
US4615966A (en) * | 1985-07-03 | 1986-10-07 | Polaroid Corporation | Color transfer photographic processes and products with indole phthalein filter dyes |
JPH02117651A (ja) * | 1988-01-20 | 1990-05-02 | Yamanouchi Pharmaceut Co Ltd | ジウレア誘導体及びその製造法 |
IE892088L (en) * | 1988-07-12 | 1990-01-12 | William Henry Deryk Morris | Quinoline derivatives, their production and use |
JPH0753714B2 (ja) * | 1988-07-12 | 1995-06-07 | 武田薬品工業株式会社 | Acat阻害剤、キノリン誘導体及びその製造法 |
EP0375133A1 (de) * | 1988-11-14 | 1990-06-27 | The Upjohn Company | Alpha-amino-indol-3-essigsäure, verwendbar als antidiabetische, antifettleibige und antiarteriosklerotische Agenten |
AU5279390A (en) * | 1989-03-31 | 1990-11-05 | Kyoto Pharmaceutical Industries, Ltd. | New imidazole derivatives, production thereof, and uses thereof as medicines |
JPH03181465A (ja) * | 1989-12-11 | 1991-08-07 | Takeda Chem Ind Ltd | キノリン誘導体 |
JPH0466568A (ja) * | 1990-06-29 | 1992-03-02 | Takeda Chem Ind Ltd | 中枢性抗酸化剤化合物 |
US5143919A (en) * | 1990-08-17 | 1992-09-01 | Takeda Chemical Industries, Ltd. | Thienopyridine derivatives and their pharmaceutical use |
US5256782A (en) * | 1990-08-17 | 1993-10-26 | Takeda Chemical Industries, Ltd. | Thienopyridine derivatives which are intermediates |
FR2673625B1 (fr) * | 1991-03-08 | 1993-05-07 | Adir | Nouveaux derives d'acylaminophenol, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
US5254919A (en) | 1991-03-22 | 1993-10-19 | Eastman Kodak Company | Encoder system using linear array sensor for high resolution |
FR2674522B1 (fr) * | 1991-03-26 | 1993-07-16 | Lipha | Nouveaux derives de l'indole, procedes de preparation et medicaments les contenant. |
JPH0825973B2 (ja) * | 1991-04-12 | 1996-03-13 | シェリング・コーポレーション | アシル補酵素a:コレステロールアシルトランスフェラーゼの阻害剤としての二環式アミド |
IL101785A0 (en) | 1991-05-10 | 1992-12-30 | Fujisawa Pharmaceutical Co | Urea derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same |
WO1994014801A1 (en) * | 1992-12-29 | 1994-07-07 | Smithkline Beecham Plc | Heterocyclic urea derivatives as 5ht2c and 5ht2b antagonists |
JP3720395B2 (ja) | 1994-09-20 | 2005-11-24 | 京都薬品工業株式会社 | 新規ヘテロ環誘導体、その製造方法およびその医薬用途 |
CZ292632B6 (cs) * | 1995-10-05 | 2003-11-12 | Kyoto Pharmaceutical Industries, Ltd. | Indolinový, indolový nebo tetrahydrochinolinový derivát a farmaceutický přípravek s jeho obsahem |
-
1994
- 1994-09-20 JP JP22516694A patent/JP3720395B2/ja not_active Expired - Fee Related
-
1995
- 1995-09-20 US US08/809,242 patent/US5990150A/en not_active Expired - Fee Related
- 1995-09-20 PT PT95932172T patent/PT782986E/pt unknown
- 1995-09-20 DE DE69531213T patent/DE69531213T2/de not_active Expired - Fee Related
- 1995-09-20 KR KR1019970701786A patent/KR100365503B1/ko not_active IP Right Cessation
- 1995-09-20 WO PCT/JP1995/001873 patent/WO1996009287A1/ja active IP Right Grant
- 1995-09-20 AU AU35324/95A patent/AU693261B2/en not_active Ceased
- 1995-09-20 AT AT01114083T patent/ATE255091T1/de not_active IP Right Cessation
- 1995-09-20 AT AT95932172T patent/ATE244220T1/de not_active IP Right Cessation
- 1995-09-20 ES ES01114083T patent/ES2206367T3/es not_active Expired - Lifetime
- 1995-09-20 DK DK95932172T patent/DK0782986T3/da active
- 1995-09-20 EP EP01114083A patent/EP1136474B1/de not_active Expired - Lifetime
- 1995-09-20 EP EP95932172A patent/EP0782986B1/de not_active Expired - Lifetime
- 1995-09-20 ES ES95932172T patent/ES2200003T3/es not_active Expired - Lifetime
- 1995-09-20 DK DK01114083T patent/DK1136474T3/da active
- 1995-09-20 PT PT01114083T patent/PT1136474E/pt unknown
- 1995-09-20 DE DE69532216T patent/DE69532216T2/de not_active Expired - Fee Related
- 1995-09-20 CA CA002200472A patent/CA2200472A1/en not_active Abandoned
-
1999
- 1999-08-12 US US09/373,163 patent/US6414012B1/en not_active Expired - Fee Related
- 1999-08-12 US US09/373,509 patent/US6127403A/en not_active Expired - Fee Related
-
2001
- 2001-02-15 US US09/784,434 patent/US6489475B2/en not_active Expired - Fee Related
-
2002
- 2002-03-13 HK HK02101935.4A patent/HK1040513B/zh not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
HK1040513A1 (en) | 2002-06-14 |
EP1136474A1 (de) | 2001-09-26 |
DE69531213T2 (de) | 2004-04-15 |
WO1996009287A1 (fr) | 1996-03-28 |
HK1040513B (zh) | 2004-06-18 |
KR100365503B1 (ko) | 2003-06-12 |
JPH0892210A (ja) | 1996-04-09 |
DK0782986T3 (da) | 2003-10-06 |
DE69532216T2 (de) | 2004-09-16 |
US20010014740A1 (en) | 2001-08-16 |
US6489475B2 (en) | 2002-12-03 |
EP1136474B1 (de) | 2003-11-26 |
DE69532216D1 (de) | 2004-01-08 |
EP0782986A4 (de) | 2000-04-05 |
EP0782986B1 (de) | 2003-07-02 |
US6414012B1 (en) | 2002-07-02 |
AU693261B2 (en) | 1998-06-25 |
KR970706252A (ko) | 1997-11-03 |
JP3720395B2 (ja) | 2005-11-24 |
DK1136474T3 (da) | 2004-02-23 |
US5990150A (en) | 1999-11-23 |
ATE255091T1 (de) | 2003-12-15 |
US6127403A (en) | 2000-10-03 |
ES2206367T3 (es) | 2004-05-16 |
DE69531213D1 (de) | 2003-08-07 |
PT1136474E (pt) | 2004-04-30 |
PT782986E (pt) | 2003-11-28 |
ES2200003T3 (es) | 2004-03-01 |
AU3532495A (en) | 1996-04-09 |
EP0782986A1 (de) | 1997-07-09 |
CA2200472A1 (en) | 1996-03-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE244220T1 (de) | Neue heterocyclische verbindungen, verfahren zu deren herstellung sowie medizinische verwendung | |
DE59402222D1 (de) | Substituierte heterocyclische Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel | |
ATE246190T1 (de) | Heterozyklische verbindungen, verfahren zu ihrer herstellung, pharmazeutische zusammensetzungen die diese enthalten und ihre anwendung in der behandlung von diabetis und verwandten krankheiten | |
HK1015781A1 (en) | Novel heterocyclic derivatives and medicinal use thereof | |
HUP0301749A2 (hu) | Acilfenil-karbamid-származékok, eljárás az elżállításukra és gyógyszerkénti alkalmazásuk | |
ATE205712T1 (de) | Verwendung von 2-phenyl-3-aroylbenzothiophen derivaten zur herstellung eines medikaments zur hemmung der angiogenese und angiogene krankheiten | |
PL304063A1 (en) | Derivatives of 5-amino 9-methyl-7-pyrolidine-quinoline-3-carboxylic acid, method of obtaining them, pharmaceutic agent containing such compounds and medical treatment method employing them | |
ATE420853T1 (de) | 5-amidino-2-hydroxybenzolsulfonamidderivate, pharmazeutischen zusammensetzungen, die diese verbindungen enthalten, und zwischenprodukte zu deren herstellung | |
DE68919378D1 (de) | Thienotriazolodiazepine und ihre pharmazeutische Verwendung. | |
CA2053477A1 (en) | Heterocyclic amine derivatives, their production and use | |
ATE159029T1 (de) | Phosphonsäurederivate, verfahren zur herstellung und ihre verwendung | |
ATE165822T1 (de) | Chinolin-4-carbonylguanidin-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen | |
US5434177A (en) | Imidazoles for the treatment of age-related cognitive disorders and alzheimer | |
ATE123493T1 (de) | 3-(1h-indazol-3-yl)-4-pyridiname, verfahren und zwischenprodukte zu ihrer herstellung und ihre verwendung als arzneimittel. | |
NO891071L (no) | Fremgangsmaate for fremstilling av 4,5,6,7-tetrahydro-isotiazolo(4,5-c)-pyridinderivater og isomere. | |
DE69713648D1 (de) | Benzopyranderivate und ihre Verwendung zur Behandlung von Herzkrankheiten | |
DE68914600D1 (de) | Kondensierte heterocyclische Derivate von 1,2,3,4-Tetrahydroacridin, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament. | |
DE3671017D1 (de) | Benzo(c)-1,5-naphthyridine, ein verfahren und zwischenprodukte zu ihrer herstellung und ihre verwendung als arzneimittel. | |
ATE124692T1 (de) | 1,4-benzodioxanderivate, verfahren zu deren herstellung, pharmakologische zusammensetzung und deren verwendung. | |
HUP9900916A2 (hu) | Benzotiofénszármazékok felhasználása az érszövetek kalciumvezetékeit antagonizáló hatású gyógyszerkészítmények előállítására | |
AU2013888A (en) | Uricosuric composition | |
HU217346B (hu) | Eljárás amlodipin-bezilát előállítására | |
JPH03148283A (ja) | チアゾール誘導体またはその塩ならびにこれらを含有する抗潰瘍剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 0782986 Country of ref document: EP |
|
REN | Ceased due to non-payment of the annual fee |